Entera Bio Ltd.
ENTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1 |
| % Growth | – | -100% | -76.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | $0 |
| % Margin | 5% | – | -23.1% | 34.7% |
| R&D Expenses | $4 | $4 | $6 | $7 |
| G&A Expenses | $5 | $0 | $0 | $6 |
| SG&A Expenses | $5 | $4 | $7 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $10 | $9 | $13 | $12 |
| Operating Income | -$10 | -$9 | -$13 | -$12 |
| % Margin | -5,295.6% | – | -9,752.2% | -2,139.6% |
| Other Income/Exp. Net | $0 | $0 | $0 | -$0 |
| Pre-Tax Income | -$10 | -$9 | -$13 | -$12 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$10 | -$9 | -$13 | -$12 |
| % Margin | -5,271.3% | – | -9,754.5% | -2,134.3% |
| EPS | -0.25 | -0.31 | -0.45 | -0.47 |
| % Growth | 19.4% | 31.1% | 4.3% | – |
| EPS Diluted | -0.25 | -0.31 | -0.45 | -0.47 |
| Weighted Avg Shares Out | 38 | 29 | 29 | 26 |
| Weighted Avg Shares Out Dil | 38 | 29 | 29 | 26 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$10 | -$9 | -$13 | -$12 |
| % Margin | -5,270.2% | – | -9,604.5% | -2,130.3% |